
News|Articles|July 9, 2007
Latebreakers: Once daily PAH drug OK'd
Ambrisentan (Letairis) in 5-and 10-mg tablets has been approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Addressing Depression Symptoms Can Significantly Improve Asthma Outcomes
2
President Trump Signs Sweeping, Unprecedented Federal PBM Reform
3
What the Newest Landmark PBM Reform Means for the Pharmacy Industry
4
TrumpRx Officially Launches, Introduces Drug Prices
5























